NEW YORK (GenomeWeb) – The Global Medical Excellence Cluster (GMEC), a UK non-profit focused on advancing translational research, has inked an agreement with Pfizer to use molecular and genomic technologies to develop medicines for treating rare diseases.

Under the five-year initiative, investigators at GMEC's partnering universities will work with Pfizer scientists in joint programs aiming to translate basic research into new drugs for treating rare diseases, GMEC said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.